Bausch Health Companies (NYSE:BHC) Trading Down 6.9% - Should You Sell?

Shares of Bausch Health Companies Inc. (NYSE:BHC - Get Free Report) dropped 6.9% on Monday . The company traded as low as $4.78 and last traded at $4.75. Approximately 444,563 shares were traded during mid-day trading, a decline of 84% from the average daily volume of 2,703,328 shares. The stock had previously closed at $5.10.

Wall Street Analyst Weigh In

BHC has been the subject of several recent research reports. StockNews.com cut shares of Bausch Health Companies from a "buy" rating to a "hold" rating in a research report on Wednesday. Jefferies Financial Group reiterated a "hold" rating and issued a $8.00 target price (down from $12.00) on shares of Bausch Health Companies in a report on Thursday, February 6th. Finally, Royal Bank of Canada cut their price target on Bausch Health Companies from $9.00 to $8.50 and set a "sector perform" rating on the stock in a report on Monday, April 7th. One analyst has rated the stock with a sell rating and seven have issued a hold rating to the company. Based on data from MarketBeat, Bausch Health Companies currently has a consensus rating of "Hold" and an average price target of $7.17.

Bausch Health Companies Trading Down 2.5 %

The stock has a fifty day simple moving average of $6.25 and a 200-day simple moving average of $7.34. The company has a market capitalization of $1.97 billion, a PE ratio of -44.54, a P/E/G ratio of 0.37 and a beta of 0.43.

Bausch Health Companies (NYSE:BHC - Get Free Report) last announced its quarterly earnings results on Wednesday, February 19th. The company reported $1.21 earnings per share (EPS) for the quarter, missing analysts' consensus estimates of $1.65 by ($0.44). Bausch Health Companies had a negative net margin of 0.48% and a negative return on equity of 577.82%. The business had revenue of $2.56 billion during the quarter, compared to analyst estimates of $2.51 billion. As a group, equities research analysts predict that Bausch Health Companies Inc. will post 4.41 EPS for the current year.

Institutional Investors Weigh In On Bausch Health Companies

Several hedge funds and other institutional investors have recently bought and sold shares of BHC. SG Americas Securities LLC grew its holdings in shares of Bausch Health Companies by 62.0% during the fourth quarter. SG Americas Securities LLC now owns 3,301,981 shares of the company's stock worth $26,614,000 after purchasing an additional 1,263,706 shares during the last quarter. Range Financial Group LLC purchased a new position in Bausch Health Companies during the 4th quarter worth approximately $1,004,000. Geode Capital Management LLC increased its position in Bausch Health Companies by 20.5% during the third quarter. Geode Capital Management LLC now owns 636,082 shares of the company's stock worth $6,448,000 after buying an additional 108,269 shares during the period. Vanguard Group Inc. lifted its stake in Bausch Health Companies by 1.3% in the fourth quarter. Vanguard Group Inc. now owns 11,684,859 shares of the company's stock valued at $94,460,000 after buying an additional 145,078 shares during the last quarter. Finally, Raymond James Financial Inc. acquired a new stake in shares of Bausch Health Companies in the fourth quarter valued at approximately $180,000. 78.65% of the stock is currently owned by institutional investors and hedge funds.

Bausch Health Companies Company Profile

Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.